IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
K Pharma,Inc. Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.	Japan	4896
Kringle Pharma,Inc. Develops regenerative HGF medicines for rare and intractable neurological diseases.	Japan	4884
Krka Develops and sells generic prescription, non-prescription, and animal health products globally.	Slovenia	KRKG
Krystal Biotech, Inc. Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.	United States of America	KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.	South Korea	307750
Kura Oncology, Inc. Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.	United States of America	KURA
KWANGDONG PHARMACEUTICAL CO.,LTD Developing drugs & health goods by integrating oriental and Western medicine.	South Korea	009290
Kyivmedpreparat A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.	Ukraine	KMED
KYONGBO PHARMACEUTICAL CO., LTD. Manufactures APIs and finished drugs, offering global CDMO services from development to production.	South Korea	214390
KYORIN Pharmaceutical Co., Ltd. Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.	Japan	4569